Pacer WealthShield ETF (PWS)
| Assets | $13.94M |
| Expense Ratio | 0.60% |
| PE Ratio | 22.87 |
| Forward PE | 18.20 |
| Shares Out | 450,000 |
| Dividend | $0.68 (2.19%) |
| Ex-Dividend Date | Sep 3, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 49.62% |
| Volume | 14,387 |
| Open | 31.16 |
| Previous Close | 31.00 |
| Day's Range | 31.12 - 31.28 |
| 52-Week Low | 30.89 |
| 52-Week High | 33.83 |
| Beta | 0.39 |
| Holdings | 393 |
| Inception Date | Dec 11, 2017 |
About PWS
Fund Home PageThe Pacer WealthShield ETF (PWS) is an exchange-traded fund that is based on the Pacer Wealth Shield Total Return index. The fund tracks an index that toggles between equity and Treasurys, or a combination of both, on a monthly basis depending on monthly moving averages. PWS was launched on Dec 11, 2017 and is issued by Pacer.
Top 10 Holdings
27.68% of assets| Name | Symbol | Weight |
|---|---|---|
| Apple Inc. | AAPL | 3.98% |
| Eli Lilly and Company | LLY | 3.65% |
| NVIDIA Corporation | NVDA | 3.48% |
| Microsoft Corporation | MSFT | 3.15% |
| Berkshire Hathaway Inc. | BRK.B | 2.74% |
| JPMorgan Chase & Co. | JPM | 2.31% |
| Johnson & Johnson | JNJ | 2.19% |
| Amazon.com, Inc. | AMZN | 2.17% |
| AbbVie Inc. | ABBV | 2.05% |
| Meta Platforms, Inc. | META | 1.96% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 3, 2026 | $0.33672 | Sep 8, 2026 |
| Jun 4, 2026 | $0.0682 | Jun 8, 2026 |
| Mar 5, 2026 | $0.01636 | Mar 9, 2026 |
| Dec 30, 2025 | $0.25922 | Jan 5, 2026 |
| Sep 4, 2025 | $0.07966 | Sep 10, 2025 |
| Jun 5, 2025 | $0.11621 | Jun 11, 2025 |
Performance
PWS had a total return of -4.13% in the past year, including dividends. Since the fund's inception, the average annual return has been 3.89%.
News
ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of CSTI-500 for Prader-Willi Syndrome
RENSSELAER, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. (“ConSynance”), a clinical-stage biotechnology company developing first-in-class therapies for neurobehavioral symptom...
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing throug...
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in ...
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Saniona Receives Positive Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS)
PRESS RELEASE